FDA Approves Roche’s Tecentriq for Metastatic Non-Small Cell Lung Cancer

The FDA has approved Roche’s Tecentriq (atezolizumab) as a first-line monotherapy for metastatic non-small cell lung cancer (NSCLC) patients whose tumors have high PD-L1 expression.

The approval was based on the results of a phase 3 trial, which showed that Tecentriq as a monotherapy improved overall survival by 7.1 months compared with chemotherapy.

Tecentriq has received four approvals for NSCLC, including as a single agent or in combination with targeted therapies or chemotherapies.